-
1
-
-
84955465082
-
-
Hepatitis C key facts. WHO factsheet No 164. July 2013. 2013.
-
World Health Organization. Hepatitis C key facts. WHO factsheet No 164. July 2013. 2013.
-
-
-
-
2
-
-
84867308646
-
Global burden of hepatitis C: considerations for healthcare providers in the United States
-
Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55(Suppl. 1): S10-5.
-
(2012)
Clin Infect Dis
, vol.55
, pp. S10-S15
-
-
Averhoff, F.M.1
Glass, N.2
Holtzman, D.3
-
3
-
-
84872026806
-
Current management and perspectives for HCV recurrence after liver transplantation
-
Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013; 33(Suppl. 1): 56-62.
-
(2013)
Liver Int
, vol.33
, pp. 56-62
-
-
Coilly, A.1
Roche, B.2
Samuel, D.3
-
4
-
-
84882907540
-
Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C
-
Accessed 27 November 2015.
-
American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available at http://www.hcvguidelines.org/fullreport/hcv-testing-and-linkage-care. Accessed 27 November 2015.
-
-
-
-
5
-
-
84931560807
-
EASL Recommendations on Treatment of Hepatitis C 2015
-
European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236.
-
(2015)
J Hepatol
, vol.63
, pp. 199-236
-
-
-
6
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
Jacobson IM, McHutchison JG, Dusheiko G, etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
-
7
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
Poordad F, McCone J Jr, Bacon BR, etal. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone, J.2
Bacon, B.R.3
-
8
-
-
84906053496
-
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
-
Jacobson IM, Dore GJ, Foster GR, etal. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-13.
-
(2014)
Lancet
, vol.384
, pp. 403-413
-
-
Jacobson, I.M.1
Dore, G.J.2
Foster, G.R.3
-
9
-
-
84877730954
-
Sofosbuvir for previously untreated chronic hepatitis C infection
-
Lawitz E, Mangia A, Wyles D, etal. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
-
(2013)
N Engl J Med
, vol.368
, pp. 1878-1887
-
-
Lawitz, E.1
Mangia, A.2
Wyles, D.3
-
10
-
-
77952035218
-
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
-
Gao M, Nettles RE, Belema M, etal. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
-
(2010)
Nature
, vol.465
, pp. 96-100
-
-
Gao, M.1
Nettles, R.E.2
Belema, M.3
-
11
-
-
84866334428
-
Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)
-
McPhee F, Sheaffer AK, Friborg J, etal. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012; 56: 5387-96.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 5387-5396
-
-
McPhee, F.1
Sheaffer, A.K.2
Friborg, J.3
-
12
-
-
84969429096
-
Discovery of BMS-791325, an allosteric NS5B replicase inhibitor for the treatment of hepatitis C virus [abstract]
-
Kadow J, Gentles RG, Ding M, etal. Discovery of BMS-791325, an allosteric NS5B replicase inhibitor for the treatment of hepatitis C virus [abstract]. 243rd ACS National Meeting and Exposition 2012: Abstract MEDI-23.
-
243rd ACS National Meeting and Exposition 2012
-
-
Kadow, J.1
Gentles, R.G.2
Ding, M.3
-
13
-
-
84892761609
-
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection
-
Everson GT, Sims KD, Rodriguez-Torres M, etal. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146: 420-9.
-
(2014)
Gastroenterology
, vol.146
, pp. 420-429
-
-
Everson, G.T.1
Sims, K.D.2
Rodriguez-Torres, M.3
-
14
-
-
82455188181
-
Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
-
Nettles RE, Gao M, Bifano M, etal. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011; 54: 1956-65.
-
(2011)
Hepatology
, vol.54
, pp. 1956-1965
-
-
Nettles, R.E.1
Gao, M.2
Bifano, M.3
-
15
-
-
84862560600
-
Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir
-
McPhee F, Friborg J, Levine S, etal. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 2012; 56: 3670-81.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 3670-3681
-
-
McPhee, F.1
Friborg, J.2
Levine, S.3
-
16
-
-
82455192239
-
Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: invitro and invivo correlations
-
Fridell RA, Wang C, Sun JH, etal. Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: invitro and invivo correlations. Hepatology 2011; 54: 1924-35.
-
(2011)
Hepatology
, vol.54
, pp. 1924-1935
-
-
Fridell, R.A.1
Wang, C.2
Sun, J.H.3
-
17
-
-
84873054024
-
Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-alfa and ribavirin
-
McPhee F, Falk P, Lemm J, etal. Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-alfa and ribavirin. J Hepatol 2012; 56(Suppl. 2): S473.
-
(2012)
J Hepatol
, vol.56
, pp. S473
-
-
McPhee, F.1
Falk, P.2
Lemm, J.3
-
18
-
-
84856159009
-
Preliminary study of two antiviral agents for hepatitis C genotype 1
-
Lok AS, Gardiner DF, Lawitz E, etal. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.
-
(2012)
N Engl J Med
, vol.366
, pp. 216-224
-
-
Lok, A.S.1
Gardiner, D.F.2
Lawitz, E.3
-
19
-
-
84894099866
-
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
-
Lok AS, Gardiner DF, Hezode C, etal. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014; 60: 490-9.
-
(2014)
J Hepatol
, vol.60
, pp. 490-499
-
-
Lok, A.S.1
Gardiner, D.F.2
Hezode, C.3
-
20
-
-
84879693219
-
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
-
Suzuki Y, Ikeda K, Suzuki F, etal. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58: 655-62.
-
(2013)
J Hepatol
, vol.58
, pp. 655-662
-
-
Suzuki, Y.1
Ikeda, K.2
Suzuki, F.3
-
21
-
-
84857395452
-
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
-
Chayama K, Takahashi S, Toyota J, etal. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-8.
-
(2012)
Hepatology
, vol.55
, pp. 742-748
-
-
Chayama, K.1
Takahashi, S.2
Toyota, J.3
-
22
-
-
84892619580
-
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
-
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, etal. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21.
-
(2014)
N Engl J Med
, vol.370
, pp. 211-221
-
-
Sulkowski, M.S.1
Gardiner, D.F.2
Rodriguez-Torres, M.3
-
24
-
-
84955473708
-
-
™ (Simeprevir) Prescribing Information. 2014.
-
™ (Simeprevir) Prescribing Information. 2014.
-
-
-
-
25
-
-
84900339263
-
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
-
Afdhal N, Zeuzem S, Kwo P, etal. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
-
(2014)
N Engl J Med
, vol.370
, pp. 1889-1898
-
-
Afdhal, N.1
Zeuzem, S.2
Kwo, P.3
-
26
-
-
84901044326
-
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
-
Ferenci P, Bernstein D, Lalezari J, etal. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. NEngl J Med 2014; 370: 1983-92.
-
(2014)
NEngl J Med
, vol.370
, pp. 1983-1992
-
-
Ferenci, P.1
Bernstein, D.2
Lalezari, J.3
-
27
-
-
84929207643
-
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
-
Poordad F, Sievert W, Mollison L, etal. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015; 313: 1728-35.
-
(2015)
JAMA
, vol.313
, pp. 1728-1735
-
-
Poordad, F.1
Sievert, W.2
Mollison, L.3
-
28
-
-
84929208843
-
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C genotype 1 infection with compensated cirrhosis
-
Muir A, Poordad F, Lalezari JP, etal. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C genotype 1 infection with compensated cirrhosis. JAMA 2015; 313: 1736-44.
-
(2015)
JAMA
, vol.313
, pp. 1736-1744
-
-
Muir, A.1
Poordad, F.2
Lalezari, J.P.3
|